{
    "clinical_study": {
        "@rank": "89175", 
        "arm_group": [
            {
                "arm_group_label": "\u2022 Active surveillance", 
                "arm_group_type": "Other", 
                "description": "\u2022\tActive surveillance alone"
            }, 
            {
                "arm_group_label": "Enantone LP 11.25 mg + Surveillance", 
                "arm_group_type": "Active Comparator", 
                "description": "Enantone LP 11.25 mg (1 injection) + Surveillance"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this phase III clinical study is to assess two treatment strategies for\n      indolent prostate cancer and to compare their therapeutic benefit  for management of\n      patients with low-risk, localized prostate cancer (D'AMICO criteria). 2 groups of patients\n      will follow after randomisation :\n\n      Strategy A = active surveillance after a single subcutaneous injection of Enantone LP\n      11.25mg or\n\n      Strategy B = active surveillance without androgen deprivation\n\n      The benefit should be evaluated after a twelve-month follow up based on the prostate biopsy\n      results (assessed by a centralized procedure) according to the number of negative biopsies\n      in each group."
        }, 
        "brief_title": "Phase III Study : Enantone LP 11.25 mg (Leuprorelin) Effect on the Histological Progression of Indolent Prostate Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a phase III randomized multi-centre, open-labelled comparative study. It is planned\n      to include 240 patients in this study that will be conducted in 36 urologic centers treating\n      prostate cancer.\n\n      The trial population corresponds to patients with indolent biopsy-proved prostate cancer and\n      low risk according to D'AMICO criteria.\n\n      Patients will be selected 3 months before D0 visit starting from the results of former\n      biopsies and will be definitively included in D0 according to the result of another biopsy\n      that will be centrally analysed.\n\n      Patients will be examined at six evaluation time points (M-3, D0, M3, M6, M9, M12)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical stage : T1c or T2a\n\n          -  Staging biopsy comprising at least 12 cores sampled and analysed according to a\n             centralised biopsy procedure (which confirm the results of the first biopsy [presence\n             of positive cores localised in one third of the lobe (top, middle, bottom), the\n             absence of core with tumour length  > 3 mm and absence  grade  4  cell  ( Gleason <\n             7)])\n\n          -  PSA level <10 ng/ml (centralised assay)\n\n          -  PSA density < 15%\n\n          -  Dynamic MRI criteria with confirmation of clinical stage (centralised readings)\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085252", 
            "org_study_id": "FR-LEU-002", 
            "secondary_id": "2012-002653-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enantone LP 11.25 mg + Surveillance", 
                "description": "Active surveillance after a single subcutaneous injection of Enantone LP 11.25mg", 
                "intervention_name": "Enantone LP 11.25 mg (1 injection) + Surveillance", 
                "intervention_type": "Drug", 
                "other_name": "Leuproreline (Enantone) 3 months"
            }, 
            {
                "arm_group_label": "\u2022 Active surveillance", 
                "description": "Active surveillance alone", 
                "intervention_name": "active surveillance", 
                "intervention_type": "Other", 
                "other_name": "Active surveillance alone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "phase III, indolent prostate cancer", 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mehemed.ouzid@takeda.com", 
                    "last_name": "Ouzid Mehemed, MD", 
                    "phone": "00 33 1 46 25 16 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris La D\u00e9fense", 
                        "country": "France", 
                        "state": "Paris", 
                        "zip": "92977"
                    }, 
                    "name": "Ouzid"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.cussenot@tnn.aphp.fr", 
                    "last_name": "Olivier Cussenot, MD"
                }, 
                "contact_backup": {
                    "email": "mehemed.ouzid@takeda.com", 
                    "last_name": "Mehemed OUZID, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "Prof. Olivier CUSSENOT"
                }, 
                "investigator": [
                    {
                        "last_name": "Azouzi abdel-Rahm\u00e8ne, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bruyere Frank, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Chartier Eric, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Coloby Patrick, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Costa Pierre, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Malavaud Bernard, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Rozet Fran\u00e7ois, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Staerman Fr\u00e9d\u00e9ric, Reims", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mozer Pierre, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ruffion Alain, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Descotes Jean-Luc, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ravery Vincent, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jung Jean-Luc, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Davin Jean-Louis, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Leportz Benoit, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Rebillard Xavier, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Villamizar Vesga Jorge, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ansiau Jean-Pierre, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Rigaud J\u00e9r\u00f4me, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jacqmin Didier, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Irani Jacques, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Descazeaud Aur\u00e9lien, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Amiel Jean, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Benchetrit Jacques, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fendler Jean-Philippe, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Thuret Rodolphe, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marc Bernard, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Houlgatte Alain, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Misrai Vincent, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Vincendeau S\u00e9bastien, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Larre St\u00e9phane, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Delavierre Dominique, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pfister Christian, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer", 
        "overall_contact": {
            "email": "mehemed.ouzid@takeda.com", 
            "last_name": "Ouzid Mehemed, MD", 
            "phone": "00 33 1 46 25 16 71"
        }, 
        "overall_official": {
            "affiliation": "Tenon Hospital Paris France", 
            "last_name": "Olivier CUSSENOT, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Staging biopsy comprising at least 12 cores sampled and analysed according to a centralised biopsy procedure (which confirm the results of the first biopsy [presence of positive cores localised in one third of the lobe (top, middle, bottom), the absence of core with tumour length  > 3 mm and absence  grade  4  cell  ( Gleason < 7)", 
            "measure": "Comparison of the number of patients with negative biopsies at 12 months", 
            "safety_issue": "No", 
            "time_frame": "2 prostate biopsies in 12 months (at M0 / M12)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "the number of patients with Gleason score  \u2265 7", 
                "measure": "Gleason score Anxiety evaluation (HADS)/ Erectile function evaluation", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "Disease clinical symptoms evaluation at each visit / 3 months", 
                "measure": "the progression over time of disease clinical symptoms (IPSS score)", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "2 MRI during the 12 months-period", 
                "measure": "the tumour radiological progression by dynamic MRI", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "biological assay at each visit (every 3 months)", 
                "measure": "the PSA levels progression", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "every three months at each visit by using HADs questionnaire", 
                "measure": "the anxiety score on HAD Scale", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "erectile function evaluation at each visit", 
                "measure": "the International Index of Erectile Function (IIEF-5) Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }
        ], 
        "source": "Takeda France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda France", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}